Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 95

1.

Protein engineering for therapeutics, part B. Preface.

Wittrup KD, Verdine GL.

Methods Enzymol. 2012;503:xiii-xiv. doi: 10.1016/B978-0-12-396962-0.00013-6. No abstract available.

PMID:
22230575
[PubMed - indexed for MEDLINE]
2.

Advancing protein therapeutics: current challenges in protein therapeutics -- CHI's Second Annual Conference.

He M.

IDrugs. 2006 Mar;9(3):177-8. No abstract available.

PMID:
16523380
[PubMed - indexed for MEDLINE]
3.

Recombinant therapeutic proteins: production platforms and challenges.

Dingermann T.

Biotechnol J. 2008 Jan;3(1):90-7. Review.

PMID:
18041103
[PubMed - indexed for MEDLINE]
4.

Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.

Pardridge WM, Boado RJ.

Methods Enzymol. 2012;503:269-92. doi: 10.1016/B978-0-12-396962-0.00011-2. Review.

PMID:
22230573
[PubMed - indexed for MEDLINE]
5.

Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins.

Niv R, Cohen CJ, Denkberg G, Segal D, Reiter Y.

Curr Pharm Biotechnol. 2001 Mar;2(1):19-46. Review.

PMID:
11482347
[PubMed - indexed for MEDLINE]
6.

Advances in radioimmunotherapy in the age of molecular engineering and pretargeting.

Sharkey RM, Goldenberg DM.

Cancer Invest. 2006 Feb;24(1):82-97. Review.

PMID:
16466997
[PubMed - indexed for MEDLINE]
7.

Enhancement of therapeutic protein in vivo activities through glycoengineering.

Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J.

Nat Biotechnol. 2003 Apr;21(4):414-21. Epub 2003 Mar 3.

PMID:
12612588
[PubMed - indexed for MEDLINE]
8.

Peptide revolution: genomics, proteomics and therapeutics.

Sawyer TK, Chorev M.

Biotechniques. 2003 Mar;34(3):594-6, 598-9. No abstract available.

PMID:
12661163
[PubMed - indexed for MEDLINE]
9.

Immunogenicity of protein therapeutics.

De Groot AS, Scott DW.

Trends Immunol. 2007 Nov;28(11):482-90. Epub 2007 Oct 25. Review.

PMID:
17964218
[PubMed - indexed for MEDLINE]
10.

Integrating cell-level kinetic modeling into the design of engineered protein therapeutics.

Rao BM, Lauffenburger DA, Wittrup KD.

Nat Biotechnol. 2005 Feb;23(2):191-4.

PMID:
15696150
[PubMed - indexed for MEDLINE]
11.

Protein engineering and design for drug delivery.

Murphy JR.

Curr Opin Struct Biol. 1996 Aug;6(4):541-5. Review.

PMID:
8794167
[PubMed - indexed for MEDLINE]
12.

Protein engineering for therapeutics, Part A. Preface.

Wittrup KD, Verdine GL.

Methods Enzymol. 2012;502:xiii-xiv. doi: 10.1016/B978-0-12-416039-2.00031-8. No abstract available.

PMID:
22208991
[PubMed - indexed for MEDLINE]
13.

Engineering better cytokines.

Steinman L.

Nat Biotechnol. 2003 Nov;21(11):1293-4. No abstract available.

PMID:
14595357
[PubMed - indexed for MEDLINE]
14.

Production of recombinant protein therapeutics in cultivated mammalian cells.

Wurm FM.

Nat Biotechnol. 2004 Nov;22(11):1393-8. Review.

PMID:
15529164
[PubMed - indexed for MEDLINE]
15.

Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma.

Luk JM, Wong KF.

Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):482-8. Review.

PMID:
16700883
[PubMed - indexed for MEDLINE]
16.

Manufacturing of recombinant therapeutic proteins in microbial systems.

Graumann K, Premstaller A.

Biotechnol J. 2006 Feb;1(2):164-86. Review.

PMID:
16892246
[PubMed - indexed for MEDLINE]
17.

Keeping dry and crossing membranes.

Fernández A.

Nat Biotechnol. 2004 Sep;22(9):1081-4. Review. No abstract available.

PMID:
15340471
[PubMed - indexed for MEDLINE]
18.

Engineering S-protein fragments of bovine ribonuclease A for targeted drug delivery.

Backer MV, Gaynutdinov TI, Aloise R, Przekop K, Backer JM.

Protein Expr Purif. 2002 Dec;26(3):455-61.

PMID:
12460770
[PubMed - indexed for MEDLINE]
19.

Recombinant hCG (OVIDREL) and recombinant interferon-beta1a (REBIF) (No. 13 in a series of articles to promote a better understanding of the use of genetic engineering).

Piani D, Malkowski JP.

J Biotechnol. 2001 May 18;87(3):281-3. No abstract available.

PMID:
11474553
[PubMed - indexed for MEDLINE]
20.

Antibody engineering and modification technologies.

Filpula D.

Biomol Eng. 2007 Jun;24(2):201-15. Epub 2007 Mar 31. Review.

PMID:
17466589
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk